Functional MRI for anticancer therapy assessment.

Anticancer drug discovery and development are experiencing a paradigm shift from cytotoxic therapies to more selective therapies that target underlying oncogenic abnormalities. Many newer therapies are cytostatic, for which objective tumour shrinkage is an inappropriate response parameter. There is a growing need to develop surrogate endpoints of drug efficacy to speed up the process of finding effective drug combinations for phase III trials. This review focuses on the developing field of functional magnetic resonance imaging (MRI) and its potential applications in the pharmacodynamic evaluation of existing and new cancer therapeutics. Dynamic contrast enhanced MRI, which is currently being used to evaluate anti-angiogenic, and anti-vascular agents in human trials will be reviewed in detail. The requirements that must be met before incorporating functional MRI techniques into clinical protocols are also discussed.

[1]  O. Hoekstra,et al.  Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  H. Degani,et al.  Dynamic contrast-enhanced magnetic resonance imaging reveals stress-induced angiogenesis in MCF7 human breast tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Matsubayashi,et al.  Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. , 2000, Radiology.

[4]  G Johnson,et al.  Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. , 1999, Radiology.

[5]  N Karssemeijer,et al.  Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imaging. , 1996, Radiology.

[6]  R I Grossman,et al.  Gliomas: correlation of magnetic susceptibility artifact with histologic grade. , 1997, Radiology.

[7]  R. Weissleder.  Molecular imaging: exploring the next frontier. , 1999, Radiology.

[8]  J. Griffiths,et al.  Nuclear magnetic resonance spectroscopy of cancer. , 1997, The British journal of radiology.

[9]  I. Gribbestad,et al.  Comparative signal intensity measurements in dynamic gadolinium‐enhanced MR mammography , 1994, Journal of magnetic resonance imaging : JMRI.

[10]  Risto A. Kauppinen,et al.  Quantitative assessment of blood flow, blood volume and blood oxygenation effects in functional magnetic resonance imaging , 1998, Nature Medicine.

[11]  G. Newstead,et al.  MR imaging of the breast. , 1995, Radiology.

[12]  B. Rosen,et al.  Susceptibility contrast imaging of cerebral blood volume: Human experience , 1991, Magnetic resonance in medicine.

[13]  D J Hawkes,et al.  CT estimations of mean attenuation values and volume in testicular tumors: a comparison with surgical and histologic findings. , 1982, Radiology.

[14]  D Artemov,et al.  Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. , 2001, Neoplasia.

[15]  J R Griffiths,et al.  BOLD MRI of human tumor oxygenation during carbogen breathing , 2001, Journal of magnetic resonance imaging : JMRI.

[16]  M. Neeman,et al.  Analysis of subcutaneous angiogenesis by gradient echo magnetic resonance imaging , 1998, Magnetic resonance in medicine.

[17]  K. Zierler.  Theory of Use of Indicators to Measure Blood Flow and Extracellular Volume and Calculation of Transcapillary Movement of Tracers , 1963 .

[18]  B. Escudier,et al.  Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Rakesh K. Jain,et al.  Transport of molecules across tumor vasculature , 2004, Cancer and Metastasis Reviews.

[20]  D M Shames,et al.  MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. , 2001, Radiology.

[21]  P.-F. Liu,et al.  MRI of the uterus, uterine cervix, and vagina: diagnostic performance of dynamic contrast-enhanced fast multiplanar gradient-echo imaging in comparison with fast spin-echo T2-weighted pulse imaging , 1998, European Radiology.

[22]  W. Kaiser,et al.  MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. , 1989, Radiology.

[23]  G Brix,et al.  Pathophysiologic basis of contrast enhancement in breast tumors , 1999, Journal of magnetic resonance imaging : JMRI.

[24]  J. Witjes,et al.  Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. , 1998, Radiology.

[25]  O. Haraldseth,et al.  Differentiating Benign and Malignant Breast Lesions with T2*-Weighted First Pass Perfusion Imaging , 1999, Acta radiologica.

[26]  W E Reddick,et al.  MR imaging of tumor microcirculation: Promise for the new millenium , 1999, Journal of magnetic resonance imaging : JMRI.

[27]  D M Shames,et al.  Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. , 1996, Radiology.

[28]  P S Tofts,et al.  Quantitative Analysis of Dynamic Gd‐DTPA Enhancement in Breast Tumors Using a Permeability Model , 1995, Magnetic resonance in medicine.

[29]  A. Padhani,et al.  Non‐invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer , 2001, The British journal of surgery.

[30]  S. Kety.  The theory and applications of the exchange of inert gas at the lungs and tissues. , 1951, Pharmacological reviews.

[31]  Ravi S. Menon,et al.  On the characteristics of functional magnetic resonance imaging of the brain. , 1998, Annual review of biophysics and biomolecular structure.

[32]  R. Jain,et al.  Microvascular permeability of normal and neoplastic tissues. , 1986, Microvascular research.

[33]  K. Kinkel,et al.  Dynamic contrast-enhanced subtraction versus T2-weighted spin-echo MR imaging in the follow-up of colorectal neoplasm: a prospective study of 41 patients. , 1996, Radiology.

[34]  H Okamura,et al.  Dynamic contrast-enhanced MR imaging of uterine cervical cancer: pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy. , 2000, Radiology.

[35]  A. Alavi,et al.  Role of radionuclide imaging in trials of antiangiogenic therapy. , 2000, Academic radiology.

[36]  K W Ferrara,et al.  Evaluation of tumor angiogenesis with US: imaging, Doppler, and contrast agents. , 2000, Academic radiology.

[37]  W T Yuh,et al.  An exciting and challenging role for the advanced contrast MR imaging , 1999, Journal of magnetic resonance imaging : JMRI.

[38]  D P Dearnaley,et al.  Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. , 2001, Radiology.

[39]  W Zhen,et al.  Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer , 2000, Journal of magnetic resonance imaging : JMRI.

[40]  A. Tomida,et al.  Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. , 1999, Anti-cancer drug design.

[41]  P. Price,et al.  Positron emission tomography: a new investigational area for cancer research. , 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).

[42]  E F Halpern,et al.  Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. , 1994, Radiology.

[43]  W P Dillon,et al.  Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. , 2000, AJNR. American journal of neuroradiology.

[44]  W E Reddick,et al.  Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma , 1999, Journal of magnetic resonance imaging : JMRI.

[45]  P. Tofts.  Modeling tracer kinetics in dynamic Gd‐DTPA MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.

[46]  C. Crone,et al.  THE PERMEABILITY OF CAPILLARIES IN VARIOUS ORGANS AS DETERMINED BY USE OF THE 'INDICATOR DIFFUSION' METHOD. , 1963, Acta physiologica Scandinavica.

[47]  M Takahashi,et al.  Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. , 1998, AJR. American journal of roentgenology.

[48]  Michal Neeman,et al.  In Vivo Prediction of Vascular Susceptibility to Vascular Endothelial Growth Factor Withdrawal Magnetic Resonance Imaging of C6 Rat Glioma in Nude Mice , 1999 .

[49]  B R Rosen,et al.  NMR imaging of changes in vascular morphology due to tumor angiogenesis , 1998, Magnetic resonance in medicine.

[50]  Bruce R. Rosen,et al.  Echo-Planar MR Cerebral Blood Volume Mapping of Gliomas , 1995 .

[51]  A R Padhani,et al.  Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. , 2001, Clinical radiology.

[52]  M E Moseley,et al.  Comparison of Gd‐ and Dy‐chelates for T2* Contrast‐Enhanced Imaging , 1991, Magnetic resonance in medicine.

[53]  G Brix,et al.  MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. , 1994, Magnetic resonance imaging clinics of North America.

[54]  J C Ehrhardt,et al.  Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. , 1996, International journal of radiation oncology, biology, physics.

[55]  W. J. Lorenz,et al.  Quantification of regional cerebral blood flow and volume with dynamic susceptibility contrast-enhanced MR imaging. , 1994, Radiology.

[56]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[57]  B. Rosen,et al.  Contrast‐to‐noise ratio in functional MRI of relative cerebral blood volume with sprodiamide injection , 1997, Journal of magnetic resonance imaging : JMRI.

[58]  S. Heywang-Köbrunner,et al.  Contrast‐Enhanced MRI of the Breast after Limited Surgery and Radiation Therapy , 1993, Journal of computer assisted tomography.

[59]  M O Leach,et al.  Improving image quality and T(1) measurements using saturation recovery turboFLASH with an approximate K-space normalisation filter. , 2000, Magnetic resonance imaging.

[60]  J. Allison,et al.  Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI. , 1993, Magnetic resonance imaging.

[61]  G Brix,et al.  Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. , 1997, Cancer research.

[62]  R. Davis,et al.  In vivo detection and imaging of phosphatidylserine expression during programmed cell death. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Dario Neri,et al.  Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform , 1997, Nature Biotechnology.

[64]  L. Blumenson,et al.  Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions , 1997, Breast Cancer Research and Treatment.

[65]  R R Edelman,et al.  Cerebral blood flow: assessment with dynamic contrast-enhanced T2*-weighted MR imaging at 1.5 T. , 1990, Radiology.

[66]  M Kunnen,et al.  Benign and malignant musculoskeletal lesions: dynamic contrast-enhanced MR imaging--parametric "first-pass" images depict tissue vascularization and perfusion. , 1994, Radiology.

[67]  N. van Bruggen,et al.  Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. , 1998, Cancer investigation.

[68]  T. A. Smith,et al.  FDG uptake, tumour characteristics and response to therapy: A review , 1998, Nuclear medicine communications.

[69]  C K Kuhl,et al.  Breast neoplasms: T2* susceptibility-contrast, first-pass perfusion MR imaging. , 1997, Radiology.

[70]  M. Dewhirst,et al.  Magnetic resonance imaging applications in the evaluation of tumor angiogenesis. , 2001, Seminars in radiation oncology.

[71]  E. Fishman,et al.  Application of CT in the investigation of angiogenesis in oncology. , 2000, Academic radiology.

[72]  C Kremser,et al.  Monitoring of tumor microcirculation during fractionated radiation therapy in patients with rectal carcinoma: preliminary results and implications for therapy. , 2000, Radiology.

[73]  J P Logue,et al.  Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[74]  M V Knopp,et al.  Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  C. Hutchinson,et al.  Quantitative dynamic contrast enhanced MRI of recurrent pelvic masses in patients treated for cancer. , 1998, The British journal of radiology.

[76]  Characterization of hepatic lesions by perfusion-weighted MR imaging with an echoplanar sequence. , 1998, AJR. American journal of roentgenology.

[77]  F. Howe,et al.  Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging , 1999, NMR in biomedicine.

[78]  A R Padhani,et al.  In vivo monitoring of tumor angiogenesis with MR imaging. , 2000, Academic radiology.

[79]  T W Griffin,et al.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. , 1992, International journal of radiation oncology, biology, physics.

[80]  J. M. Taylor,et al.  Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. , 2000, Journal of the National Cancer Institute.

[81]  R. Edelman,et al.  Semiquantitative assessment of uterine perfusion using first pass dynamic contrast‐enhanced MR imaging for patients treated with uterine fibroid embolization , 2000 .

[82]  P. Fransson,et al.  The pelvis after surgery and radio-chemotherapy for rectal cancer studied with Gd-DTPA-enhanced fast dynamic MR imaging , 1998, European Radiology.

[83]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[84]  M. Knopp,et al.  Effect of radiation on blood volume in low-grade astrocytomas and normal brain tissue: quantification with dynamic susceptibility contrast MR imaging. , 1996, AJR. American journal of roentgenology.

[85]  K. Verstraete,et al.  Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery. , 1995, AJR. American journal of roentgenology.

[86]  A. Simmons,et al.  Effects of three different doses of a bolus injection of gadodiamide: assessment of regional cerebral blood volume maps in a blinded reader study. , 2000, AJNR. American journal of neuroradiology.

[87]  T. Roberts,et al.  Physiologic measurements by contrast‐enhanced MR imaging: Expectations and limitations , 1997, Journal of magnetic resonance imaging : JMRI.

[88]  N. van Bruggen,et al.  Assessing tumor angiogenesis using macromolecular MR imaging contrast media , 1997, Journal of magnetic resonance imaging : JMRI.

[89]  A. Giaccia,et al.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.

[90]  O Salonen,et al.  MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation. , 1999, Investigative radiology.

[91]  J L Evelhoch,et al.  Key factors in the acquisition of contrast kinetic data for oncology , 1999, Journal of magnetic resonance imaging : JMRI.

[92]  W. J. Lorenz,et al.  Pharmacokinetic Mapping of the Breast: A New Method for Dynamic MR Mammography , 1995, Magnetic resonance in medicine.

[93]  B. Rosen,et al.  Contrast agents in functional MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.

[94]  R Weissleder,et al.  Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. , 2000, European journal of cancer.

[95]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[96]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[97]  G Johnson,et al.  Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. , 2000, AJNR. American journal of neuroradiology.

[98]  B Asselain,et al.  Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinium-enhanced MR imaging. , 1993, Radiology.

[99]  L. Mchenry.  Cerebral blood flow. , 1966, The New England journal of medicine.

[100]  P J Drew,et al.  Microvessel density in invasive breast cancer assessed by dynamic gd‐dtpa enhanced MRI , 1997 .

[101]  D B Kopans,et al.  Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. , 1997, Radiology.